To scroll text in this page

Global Navigation

Investor Relations

Start of the main text

Updated Information

June 23, 2017  
Study Results of Phase I/II CHRYSALIS study for gilteritinib was published in The Lancet Oncology.
June 20, 2017  
Posted Corporate Governance Report
June 19, 2017  
Posted Notice of Resolution
June 07, 2017  
Exploratory analysis of the Phase I/II CHRYSALIS study of gilteritinib was presented at 2017 ASCO annual meeting.
June 07, 2017  
Updated clinical data of enfortumab vedotin Phase 1 study was presented at 2017 ASCO annual meeting.
May 29, 2017  
Posted Notification of Convocation of the 12th Term Annual Shareholders Meeting
May 25, 2017  
Amgen and UCB announce top-line Phase 3 data from active-comparator study of romosozumab in postmenopausal women with osteoporosis
April 27, 2017  
Posted Financial Results for FY2016
April 03, 2017  
Posted Corporate Governance Report
March 23, 2017  
Amgen announced the details of results in outcome study of evolocumab.
January 31, 2017  
Posted Financial Results for 3Q/FY2016
December 08, 2016  
Updated "R&D Meeting" Section
October 28, 2016  
Posted Financial Results for 2Q/FY2016
October 28, 2016  
Updated "IR Calendar" Section
October 12, 2016  
Updated clinical data of enfortumab vedotin (ASG-22ME) and ASG-15ME were presented at the European Society for Medical Oncology (ESMO) Congress.
August 31, 2016  
Annual Report 2016 is now available.
July 29, 2016  
Posted Financial Results for 1Q/FY2016
July 29, 2016  
Updated "IR Calendar" Section
June 29, 2016  
Posted Corporate Governance Report
June 07, 2016  
Phase-1 data of ASG-15ME and ASG-22ME were presented at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting

Main Text end
Local Navigation
Local Navigation end
Related Links